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Background
Treatment options for SCLC after failing platinum-based
(PLT) chemotherapy (CT) are limited. Combined block-
ade of programmed death-1 (PD-1) and cytotoxic
T-lymphocyte antigen-4 (CTLA-4) immune checkpoint
pathways has anti-tumor activity with a manageable
safety profile. Nivolumab is a fully human IgG4 PD-1
immune checkpoint inhibitor approved for melanoma
and squamous NSCLC in the US and for melanoma in
the EU and Japan. Interim efficacy and safety of nivolu-
mab +/- ipilimumab, a CTLA-4 checkpoint inhibitor, in
pretreated SCLC patients are reported.
Methods
Patients with progressive disease (PD) after PLT first-
line treatment were eligible, regardless of platinum sen-
sitivity, tumor PD-L1 expression, or number of prior CT
regimens. Patients were randomized to nivolumab
3 mg/kg IV Q2W or nivolumab+ipilimumab (1+1 mg/kg
or 1+3 mg/kg) IV Q3W for 4 cycles, followed by nivolu-
mab 3 mg/kg Q2W. Primary objective was objective
response rate (ORR). Additional objectives included
safety, progression-free survival (PFS), overall survival
(OS), and biomarker analysis.
Results
Of 90 patients enrolled (nivolumab, n=40; nivolumab+
ipilimumab, n=50 [nivolumab 1+ipilimumab 1, n=3;
nivolumab 1+ipilimumab 3, n=47]), 53% had ≥2 prior
regimens. Efficacy results for evaluable patients are
shown (Table 1). 20% of patients in the nivolumab arm
and 42% in the nivolumab+ipilimumab arms remain on
treatment. Discontinuations due to treatment-related
adverse events (TRAEs) occurred in 8% of nivolumab
and 11% of nivolumab+ipilimumab patients. TRAEs (all
grades) in ≥10% of patients included fatigue (18%), diar-
rhea (13%), nausea (10%), and decreased appetite (10%)
with nivolumab; and diarrhea (23%), fatigue (21%), rash
(21%), pruritus (19%), hypothyroidism (15%), hyperthyr-
oidism (13%), nausea (13%), maculopapular rash (13%),
and increased lipase (11%) with nivolumab 1+ipilimu-
mab 3. Grade 3–4 TRAEs in ≥5% of patients occurred
only in the nivolumab 1+ipilimumab 3 arm and
included diarrhea (9%) and increased lipase (6%). Pneu-
monitis occurred in 2 patients in the nivolumab arm
(grade 1–2) and 1 patient in the nivolumab 1+ipilimu-
mab 3 arm (grade 3–4). One patient in the nivolumab
1+ipilimumab 3 arm had treatment-related myasthenia
gravis with fatal outcome. Updated efficacy, safety, bio-
marker analysis, and case studies (responses in a patient
with PLT-refractory disease and in a patient after cross-
over to nivolumab/ipilimumab) will be presented.
Conclusions
In this PD-L1 unselected SCLC population with pro-
gression after PLT-CT, nivolumab monotherapy and
nivolumab+ipilimumab were generally well tolerated
with manageable toxicity. Rare severe toxicities will
require close follow-up. Durable responses occurred
with nivolumab monotherapy and in combination with
ipilimumab.
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Table 1
Nivolumab (n-40) Nivolumab + Ipilimumab (n=46)a
ORR, % 18 17
Complete response, % 0 2.2
Partial response, % 18 15
Stable disease,b % 20 37
Disease control rate, % 38 54
Progressive disease, % 53c 37
Death prior to first response assessment, % 10 6.5d
Not evaluable (no tumor assessment follow-up), % 0 2.2e
Median time to objective response (months) 1.6 2.2
Median DOR, months (95% CI) Range NR 4.1-11+ 6.9 (1.5 NR) 1,5-11,1+
DOR=duration of response; NR=not reached.
a4 of 50 patients did not reach first tumor assessment at database lock.
bOf 17 patients with stage disease in the nivolumab + ipilimumab arm, 7 had confirmed partial response after databse lock, resulting in updated ORR of 32.6%.
c1 patient had progressive disease in the spine, requiring surgery.
d1 patient died due to an unrelated adverse event, 1 patient died due to treatment-related myasthenia gravis, 1 patient died due to progressive disease.
e1 patient had an unrelated adverse event leading to permanent discontinuation, and had no post-baseline tumor assessment.
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